FDA Panel Votes 21-16 To Recommend Lowering Maximum Daily Dosage of Johnson & Johnson's (JNJ) Tylenol
More News related to JNJ
- Emerging Healthcare Launches Health Initiative
- ASP Announces Acquisition of Gloster Europe to Help Reduce Infections in Healthcare Facilities
- StockPreacher.com Issues Trading Outlook for Arena Pharmaceuticals Inc.
- Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
- Trading Outlook for BioElectronics Corporation Issued by StockPreacher.com
FDA Panel Votes 21-11 to recommend switch Johnson & Johnson (NYSE: JNJ) max dose of Tylenol to prescription only.
FDA Panel Votes 24-13 To Recommend limiting single dosage to 650mg
FDA Panel Votes 21-16 to recommend lower maximum daily dosage of Tylenol
Related Categories
FDAHot List
Stocks Mentioned
+0.20Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
